Strategic acquisitions SERB is actively expanding through high-value asset acquisitions such as Idefirix rights from Hansa Biopharma for €115 million, signaling readiness to broaden its rare disease and urgent care portfolio in Europe and MENA. This presents opportunities to approach SERB with co-development, licensing, or regional commercialization partnerships for complementary therapies or adjacent indications.

Expanded EU and beyond Recent news highlights expansion into key markets including the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland, and MENA via Idefirix rights. Potential sales opportunities exist in market access, local manufacturing collaboration, distribution partnerships, and post-launch support services for new and existing therapies.

New product launches Launch of ThyroSafe 130 mg potassium iodide tablets in the US indicates SERB’s ability to accelerate US market entry for niche essential medicines. Prospects include supplying formulations, regulatory support, clinical education, and demand forecasting services to support rapid scale-up and payer readiness.

Therapeutic diversification Acquisition of Y-mAbs Therapeutics in 2025 demonstrates SERB’s move into antibody-based therapeutics and oncology. This creates cross-sell opportunities for supply partnerships, GMP manufacturing capacity, and clinical development collaborations across rare diseases, cancer, and immunology domains.

Global reach and scale Operations across 100+ countries and a portfolio of 70+ essential medicines reflect a broad distribution network and reliability focus. Opportunities exist to position partner products for SERB’s global channels, leverage their end-to-end capabilities for co-commercialization, tiered pricing strategies, and regional market access support.